Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladderNorman Zinner
Western Clinical Research, 23441 Madison Street, Suite 140, Torrance, CA 90505, USA
Expert Opin Pharmacother 8:511-23. 2007
..On this basis, darifenacin seems to meet the standard for an effective OAB pharmacotherapy that is well-tolerated and, more importantly, minimises the risk of safety-related adverse effects...
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptomsNorman R Zinner
Western Clinical Research Inc, Torrance, California 90505, USA
Neurourol Urodyn 30:1214-9. 2011
..This pooled analysis of the 9-month open-label extensions to these studies evaluated the long-term efficacy and tolerability of trospium XR...
- Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument
Norman Zinner
Western Clinical Research, Inc, Torrance, California 90505, USA
Neurourol Urodyn 30:62-8. 2011
....
- Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder
Norman R Zinner
Western Clinical Research, 23441 Madison Street, Suite 140, Torrance, CA 90505, USA
Expert Opin Pharmacother 6:1409-20. 2005
..The fast-acting efficacy of trospium chloride, coupled with its good safety profile and tolerability, make it an important new option for treatment of OAB...
- Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder
Norman Zinner
Western Clinical Research, Inc, Los Angeles, California, USA
World J Urol 23:248-52. 2005
..Darifenacin (15 mg q.d.) provides comparable efficacy with improved tolerability versus oxybutynin (5 mg t.i.d.) in the treatment of patients with OAB...
- Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB
N Zinner
Western Clinical Research, Los Angeles, CA 90505, USA
Int J Clin Pract 60:119-26. 2006
..Further investigation of UFT is required to determine its role in evaluating urgency. The study confirmed that darifenacin 15 mg qd is an effective and well-tolerated treatment for OAB, which improves QoL...
- Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study
Norman Zinner
Western Clinical Research Inc, Torrance, CA 90505, USA
J Sex Med 4:137-44. 2007
..The clinical impact of coingestion of food and these factors has never been evaluated...
- Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis
Norman Zinner
Western Clinical Research, Inc, Torrance, California 90505, USA
Am J Geriatr Pharmacother 7:373-82. 2009
..Overactive bladder (OAB) is a common problem among the elderly and a financial burden to society. The prevalence of OAB increases with age and affects > or = 25% of people aged > or = 65 years...
- Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER
Norman Zinner
Western Clinical Research, Torrance, CA, USA
Curr Med Res Opin 24:1583-91. 2008
..Assess changes in resource utilization, work and activity impairment, and health utility among OAB patients continuing to have urgency symptoms with tolterodine ER 4 mg and willing to try solifenacin 5/10 mg...
- Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial
Norman R Zinner
Western Clinical Research Inc, Torrance, California, USA
Urology 64:1177-81. 2004
..To investigate whether testosterone surges occur on repeat injections of 3.6 or 10.8 mg goserelin (Zoladex) depot and, if so, their extent...
- Pharmacotherapy for stress urinary incontinence : present and future options
Norman R Zinner
Western Clinical Research Inc, 23441 Madison Street, Suite 130, Torrance, CA 90505, USA
Drugs 64:1503-16. 2004
..A medication such as duloxetine, if approved, would go a long way towards expanding the available treatment options for patients with SUI...
- Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients
Norman R Zinner
Doctors Urology Group, Torrance, California 90505, USA
J Am Geriatr Soc 50:799-807. 2002
..To evaluate the efficacy, safety, and tolerability of a new, once-daily extended-release (ER) formulation of tolterodine in treating overactive bladder in older (> or =65) and younger (<65) patients...
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapyN Zinner
Western Clinical Research, Inc, Torrance, CA 90505, USA
Int J Clin Pract 62:1664-74. 2008
....
- Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence
Norman R Zinner
Western Clinical Research, Inc, Torrance, CA, USA
Expert Opin Investig Drugs 12:1559-66. 2003
..Adverse events were usually observed early in treatment, were mild-to-moderate in severity and were transient. Nausea was the most common reason for discontinuation...
- Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial
Norman Zinner
Department of Urology, University of California, Los Angeles, California, USA
J Urol 171:2311-5, quiz 2435. 2004
..It also improved symptoms of OAB and quality of life...
- The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder
Norman Zinner
Indevus Pharmaceuticals, Inc, Lexington, Massachusetts, USA
J Urol 173:1639-43. 2005
..The OAB-SCS is an improvement over individual symptoms alone. It is easy to implement and interpret and it will prove to be a clinically relevant tool in clinical trials in which patient diary data are captured...
- Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence
Roger R Dmochowski
Department of Urologic Surgery, Vanderbilt University, Nashville, Tennessee, USA
J Urol 170:1259-63. 2003
..CONCLUSIONS: These phase 3 data are consistent with phase 2 data and they provide further evidence for the safety and efficacy of duloxetine as a pharmacological agent for the treatment of women with SUI...
- Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response
Richard C Bump
Lilly Research Laboratories, Indianapolis, Indiana, USA
Obstet Gynecol 102:76-83. 2003
..To investigate the relationship between the symptom of mixed urinary incontinence and incontinence severity, urodynamic findings, and treatment response...
- Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence
Roger R Dmochowski
Urology Associates of North Texas, Fort Worth, Texas, USA
J Urol 168:580-6. 2002
..CONCLUSIONS: Doses of 2.6 and 3.9 mg. oxybutynin TDS daily improve overactive bladder symptoms and quality of life, and are well tolerated. Transdermal oxybutynin is an innovative new treatment for overactive bladder...
- Duloxetine versus placebo in the treatment of stress urinary incontinence
Peggy A Norton
Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, USA
Am J Obstet Gynecol 187:40-8. 2002
..CONCLUSION: This trial provides evidence for the efficacy and safety of duloxetine as a pharmacologic agent for the treatment of stress urinary incontinence...
- Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence
Roger R Dmochowski
Department of Urology, Vanderbilt University, Nashville, Tennessee, USA
Urology 62:237-42. 2003
..OXY-TDS improves systemic safety with regard to anticholinergic side effects. Local skin irritation occurs in some OXY-TDS patients...
- Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study
Roger R Dmochowski
Department of Urology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Urology 71:449-54. 2008
..This randomized controlled trial evaluated the efficacy and tolerability of this new extended-release formulation, trospium chloride 60 mg QD...
- Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
Matthew R Smith
Massachusetts General Hospital, Cox 640, 100 Blossom St, Boston, MA 02114, USA
J Clin Oncol 23:2918-25. 2005
..To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy...
- Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies
Werner Schäfer
International Continence Society Office, Southme Hospital, Bristol, BSIO 5NB, United Kingdom
Neurourol Urodyn 21:261-74. 2002
..This does not imply that this technique is the only one possible. Rather, it means that this technique is well-established, and gives good results when used with the suggested standards of good urodynamic practice...
